Currently, there are 150.29M common shares owned by the public and among those 144.08M shares have been available to trade.
The company’s stock has a 5-day price change of -27.68% and -31.18% over the past three months. HRTX shares are trading -24.71% year to date (YTD), with the 12-month market performance up to 118.65% higher. It has a 12-month low price of $0.53 and touched a high of $3.93 over the same period. HRTX has an average intraday trading volume of 1.83 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -27.81%, -31.09%, and -50.29% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Heron Therapeutics Inc (NASDAQ: HRTX) shares accounts for 81.29% of the company’s 150.29M shares outstanding.
It has a market capitalization of $194.14M and a beta (3y monthly) value of 1.78. The earnings-per-share (ttm) stands at -$0.33. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.01% over the week and 7.81% over the month.
Earnings per share for the fiscal year are expected to increase by 85.31%, and 68.09% over the next financial year. EPS should grow at an annualized rate of 47.50% over the next five years, compared to 20.01% over the past 5-year period.
Looking at the support for the HRTX, a number of firms have released research notes about the stock. Rodman & Renshaw stated their Buy rating for the stock in a research note on June 13, 2024, with the firm’s price target at $7. CapitalOne coverage for the Heron Therapeutics Inc (HRTX) stock in a research note released on April 23, 2024 offered a Overweight rating with a price target of $6. Needham was of a view on March 13, 2024 that the stock is Buy, while Guggenheim gave the stock Buy rating on May 27, 2020, issuing a price target of $24. Needham on their part issued Buy rating on February 20, 2020.
